- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Evogene (EVGN)
Evogene stock price live, this page displays TASE EVGN stock exchange data. View the EVGN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Evogene real time stock price chart below.
What Is the Evogene Stock Price Today?
The Evogene stock price today is 170.6.
What Is the Stock Symbol for Evogene?
The stock symbol for Evogene is "EVGN."
What Stock Exchange Does Evogene Trade On?
Evogene is listed and trades on the Tel Aviv stock exchange.
Is Evogene a Good Stock to Buy?
Determining whether Evogene—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EVGN quote. (ISIN: IL0011050551)
What Is the Evogene Stock Price Today?
The Evogene stock price today is 170.6.
What Is the Stock Symbol for Evogene?
The stock symbol for Evogene is "EVGN."
What Stock Exchange Does Evogene Trade On?
Evogene is listed and trades on the Tel Aviv stock exchange.
Is Evogene a Good Stock to Buy?
Determining whether Evogene—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EVGN quote. (ISIN: IL0011050551)
170.6
+5.9(+3.58%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
167.5
173.1
52 wk Range
115.1
478.7
EVGN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
167.5173.1
52 wk Range
115.1478.7
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
EVGN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Evogene Earnings Call Summary for Q2/2026
- Evogene Q2 2026 net loss narrowed 62% to $1.8M from $4.7M YoY, but revenue fell 40% to $0.3M; shares dropped 7.8% to $165.10
- Company guided FY 2026 cash burn at $8.5M-$9.5M, down from ~$20.5M in 2024, following restructuring that cut headcount from 117 to 38 employees
- Evogene pivoted to AI-driven small-molecule discovery with six active drug collaborations; internal pharma program may reach preclinical trials H2 2027
- Cash balance stood at $9.3M as of June 30; company raised $3.2M via ATM program in Q2-Q3, adding ~2.5M shares and raising dilution concerns
- CEO Haviv cited autonomous AI agents as key efficiency driver; management expects revenue growth from R&D fees as collaboration programs advance
Last Updated: 2026-08-18, 10:14 a/m
Read Full TranscriptEarnings
Latest Release
Aug 18, 2026
EPS / Forecast
-0.13 / --
Revenue / Forecast
347K / --
Compare EVGN to Peers and Sector
Metrics to compare | EVGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEVGNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.4x | −1.7x | −0.4x | |
PEG Ratio | −0.01 | 0.02 | 0.00 | |
Price/Book | −2.3x | 1.3x | 2.6x | |
Price / LTM Sales | 4.6x | 4.1x | 3.1x | |
Upside (Analyst Target) | - | 543.5% | 48.9% | |
Fair Value Upside | Unlock | 21.4% | 6.8% | Unlock |
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Evogene (EVGN) Stock Price Today?
The Evogene stock price today is 170.6 ILS.
What Stock Exchange Does Evogene Trade On?
Evogene is listed and trades on the Tel Aviv Stock Exchange.
What Is the Stock Symbol for Evogene?
The stock symbol for Evogene is "EVGN."
What Is the Evogene Market Cap?
As of today, Evogene market cap is 23.09M ILS.
What Is Evogene's Earnings Per Share (TTM)?
The Evogene EPS (TTM) is -1.8.
From a Technical Analysis Perspective, Is EVGN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Evogene Stock Split?
Evogene has split 2 times.
How Many Employees Does Evogene Have?
Evogene has 38 employees.
What is the current trading status of Evogene (EVGN)?
As of Sep 06, 2026, Evogene (EVGN) is trading at a price of 170.6 ILS, with a previous close of 164.7 ILS. The stock has fluctuated within a day range of 167.5 ILS to 173.1 ILS, while its 52-week range spans from 115.1 ILS to 478.7 ILS.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.